New Cetuximab Dosing Guidelines Approved for Colorectal Cancer and Head and Neck Cancer

The FDA has approved a new dosing regimen of 500 mg/m2 cetuximab (Erbitux®, Eli Lilly) for patients with KRAS wild-type epidermal growth factor receptor (EGFR)–expressing metastatic colorectal cancer (CRC) and patients with head and neck squamous cell carcinoma (HNSCC). This biweekly dosage regimen serves as an alternative to the existing weekly dosage regimen of cetuximab, whether on its own or combined with chemotherapy, and should be administered as a single 120-minute intravenous infusion ev...
Continue reading

Semaphorin Contributes to Lung Cancer Treatment Resistance

Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancer (NSCLC) in patients who have epidermal growth factor receptor (EGFR) mutations. However, when patients relapse, they usually develop TKI resistance. Scientists discovered a protein called semaphorin was a piece of the drug-resistance puzzle. In a study published in JCI Insight, researchers revealed a specific semaphorin called Semaphorin 7a (SEMA7A) as a target gene of EGFR mutations that plays a significant role in a...
Continue reading

Dual-Pronged Attack on Triple-Negative Breast Cancer

Of all the major breast cancer subtypes, triple-negative breast cancer (TNBC) has the worst prognosis and the lowest chance of long-term metastasis-free survival. Because it lacks the differentiated hormone receptors used as treatment targets in other breast cancer subtypes, TNBC lacks effective targeted therapies. That may soon change: researchers at Princeton University have found a therapeutic agent that launches a dual-pronged attack on TNBC, effectively suppressing its growth and metastasis...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.